Gelteq Secures $2.5M in Critical Convertible Debt Financing After Shareholder Approval
GELS sits 45% above its 52-week low of $0.387.
Summary
Gelteq Ltd. secured $2.5 million in additional convertible debt financing after shareholder approval, providing a critical capital injection to address its liquidity challenges.
Key Events · Financing and Capital Events · GELS
-
Shareholder Approval for Debt Financing
Shareholders approved the debt financing proposal on June 18, 2026, which was a condition for the second tranche of funding.
-
Second Tranche of Debt Financing Closed
Gelteq received $2.5 million in net proceeds from the second tranche of its convertible debt financing on June 26, 2026.
-
Convertible Promissory Note Issued
A second convertible promissory note with a principal amount of $2.875 million was issued to an institutional investor.
-
Dilutive Conversion Terms
The note is convertible into ordinary shares at 93% of the lowest daily VWAP during the five trading days preceding conversion, with a floor price of $0.50 per share, indicating potential future dilution.
Analysis · GELS · Life Sciences
This filing confirms the successful closing of the second tranche of a previously announced debt financing, bringing in $2.5 million in net proceeds. This capital is crucial for Gelteq, especially following a recent report highlighting a critical cash balance and worsening working capital deficit. While the convertible note, with its discounted conversion price and original issue discount, implies potential future dilution for existing shareholders, securing this funding is a significant step towards extending the company's operational runway and mitigating immediate financial distress.
At the time of this filing, GELS was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.39 to $2.02. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.